… of COPD and asthma. We believe that the once daily dosing of a bronchodilator would be
a … in patients with asthma and COPD. The only limits set for the development of a long-lasting …

… Several LAMAs are clinically tested in monotherapy or in combination with known or novel
β2-agonists for COPD and a number of these drugs are being under investigation for asthma …

… novel inhaled long-acting antimuscarinic agents are currently being developed, but their
role in the treatment of asthma is … treating patients suffering from asthma, some novel once-daily …

… January 1998 to August 2001 concerning bronchodilators, with special emphasis on their …
which include asthma and COPD. Bronchodilators are the mainstay for the COPD and asthma …

… on asthma endotypes, novel drugs could provide the opportunity to personalize asthma …
A prespecified subgroup with high bronchodilator reversibility reported improved scores on …

… Furthermore, existing and novel bronchodilators have become vital components of multiple
… agonists relieve bronchoconstriction in a mouse model of asthma [47]. Inhaled dual PDE3/…

… Because animal models of asthma suggested that the bronchodilator effects of racemic
albuterol are associated with the (R)-enantiomer but the main side effects of tachycardia, tremor …

… The clinical effectiveness of a number of once a day inhaled β 2 -agonists and muscarinic
antagonists is a major advance providing sustained bronchodilation in asthma and COPD. …

… subjects, compared to a bronchodilator effect in asthmatic patients. … on novel types of PDE
that have not yet been characterised. Further studies on the effect of theophylline in asthmatic …

… Because of the central role of bronchodilators in the treatment of respiratory diseases… novel
classes of broncholytic drugs. It can be hypothesized that a longer duration of bronchodilation …